Review



ccl28  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems ccl28
    (A) Representative histograms showing surface CCR10 expression on IgE + (red) and IgG1 + (blue) gated cells; the filled grey histogram shows the isotype control staining. The accompanying graph shows CCR10 MFI on the gated IgE + and IgG1 + cells. (B) Representative plots of CCR10 expression on IgE + and IgG1 + GC-like B cells, PBs, and PCs. CCR10 MFI across the different IgE + and IgG1 + cell populations from several experiments. (C) The dot plots show the frequency of IgE + and IgG1 + cells after 3h of migration in response to RPMI only or two different concentrations of <t>CCL28,</t> 25nM (300 ng/mL) and 125nM (1.5 μg/mL). (D) CCL28 induced migration shown as a percentage of the IgE + and IgG1 + cells migrating in response to RPMI control. (E) The migration capacity of IgE + and IgG1 + GC-like B cells, plamablasts, and PC in response to CCL28. (F) CCL28 induced migration shown as a percentage of the cells migrating in response to RPMI control. Data are mean + s.d. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison test (B, D, F) or paired two-tailed t -test with Welch’s correction (A); *p< 0.05; **p< 0.01.
    Ccl28, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccl28/Recombinant+Human+CCL28+Protein%2C+CF/bio_rxiv__64898__2025__12__18__695109-133-29-30
    Average 93 stars, based on 5 article reviews
    ccl28 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "IgE-producing cells on the move: CCR2 is a key regulator of IgE + plasma cell migration"

    Article Title: IgE-producing cells on the move: CCR2 is a key regulator of IgE + plasma cell migration

    Journal: bioRxiv

    doi: 10.64898/2025.12.18.695109

    (A) Representative histograms showing surface CCR10 expression on IgE + (red) and IgG1 + (blue) gated cells; the filled grey histogram shows the isotype control staining. The accompanying graph shows CCR10 MFI on the gated IgE + and IgG1 + cells. (B) Representative plots of CCR10 expression on IgE + and IgG1 + GC-like B cells, PBs, and PCs. CCR10 MFI across the different IgE + and IgG1 + cell populations from several experiments. (C) The dot plots show the frequency of IgE + and IgG1 + cells after 3h of migration in response to RPMI only or two different concentrations of CCL28, 25nM (300 ng/mL) and 125nM (1.5 μg/mL). (D) CCL28 induced migration shown as a percentage of the IgE + and IgG1 + cells migrating in response to RPMI control. (E) The migration capacity of IgE + and IgG1 + GC-like B cells, plamablasts, and PC in response to CCL28. (F) CCL28 induced migration shown as a percentage of the cells migrating in response to RPMI control. Data are mean + s.d. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison test (B, D, F) or paired two-tailed t -test with Welch’s correction (A); *p< 0.05; **p< 0.01.
    Figure Legend Snippet: (A) Representative histograms showing surface CCR10 expression on IgE + (red) and IgG1 + (blue) gated cells; the filled grey histogram shows the isotype control staining. The accompanying graph shows CCR10 MFI on the gated IgE + and IgG1 + cells. (B) Representative plots of CCR10 expression on IgE + and IgG1 + GC-like B cells, PBs, and PCs. CCR10 MFI across the different IgE + and IgG1 + cell populations from several experiments. (C) The dot plots show the frequency of IgE + and IgG1 + cells after 3h of migration in response to RPMI only or two different concentrations of CCL28, 25nM (300 ng/mL) and 125nM (1.5 μg/mL). (D) CCL28 induced migration shown as a percentage of the IgE + and IgG1 + cells migrating in response to RPMI control. (E) The migration capacity of IgE + and IgG1 + GC-like B cells, plamablasts, and PC in response to CCL28. (F) CCL28 induced migration shown as a percentage of the cells migrating in response to RPMI control. Data are mean + s.d. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison test (B, D, F) or paired two-tailed t -test with Welch’s correction (A); *p< 0.05; **p< 0.01.

    Techniques Used: Expressing, Control, Staining, Migration, Comparison, Two Tailed Test

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: Bovine CCL28 Mediates Chemotaxis via CCR10 and Demonstrates Direct Antimicrobial Activity against Mastitis Causing Bacteria
    Article Snippet: .. All reagents used in ELISA assays were marketed as the Human CCL28 DuoSet ELISA kit, although designed for detection of human CCL28, these reagents were found to cross react with bCCL28 with a sensitivity of ~5ng/ml (R&D Systems, Minneapolis, MN, USA). ..

    Affinity Purification:

    Article Title: Regulated production of the chemokine CCL28 in human colon epithelium.
    Article Snippet: Recombinant human (rh) IL-1 , IL-6, IFN- , and TNF- were from Peprotech (Rocky Hill, NJ). .. Mouse IgG1 and sodium butyrate were from Sigma (St. Louis, MO). rhCCL28, biotinconjugated affinity-purified goat anti-human CCL28, and murine MAb to human CCL28 (clone 62705) were from R&D Systems (Minneapolis, MN). .. Cy3-conjugated goat anti-mouse IgG was from Jackson ImmunoResearch Laboratories (West Grove, PA).

    Recombinant:

    Article Title: Hypoxia induced CCL28 promotes angiogenesis in lung adenocarcinoma by targeting CCR3 on endothelial cells
    Article Snippet: .. Then complete culture medium containing different concentrations of recombinant human CCL28 (R&D Systems, USA, 0 ng/ml, 1000 ng/ml, 2000 ng/ml) was added to the cells. .. Photos were taken with a Zeiss inverted microscope at 0 h and again after every 6 hours at the same positions.

    Article Title: Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma.
    Article Snippet: Dual-Luciferase Reporter Assay System (Promega, USA) was used to detect the luciferase activity after 48-h incubation. .. Chromatin Immunoprecipitation (ChIP) Briefly, pericytes treated with or without recombinant human CCL28 or CCR3 (R&D Systems, MAB155-100) neutralizing antibodies were collected and fixed by adding a cross-linking agent, formaldehyde, to stabilize the interactions between chromatin proteins and DNA. ..

    Article Title: Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma
    Article Snippet: Dual-Luciferase Reporter Assay System (Promega, USA) was used to detect the luciferase activity after 48-h incubation. .. Briefly, pericytes treated with or without recombinant human CCL28 or CCR3 (R&D Systems, MAB155-100) neutralizing antibodies were collected and fixed by adding a cross-linking agent, formaldehyde, to stabilize the interactions between chromatin proteins and DNA. ..

    Chromatin Immunoprecipitation:

    Article Title: Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma.
    Article Snippet: Dual-Luciferase Reporter Assay System (Promega, USA) was used to detect the luciferase activity after 48-h incubation. .. Chromatin Immunoprecipitation (ChIP) Briefly, pericytes treated with or without recombinant human CCL28 or CCR3 (R&D Systems, MAB155-100) neutralizing antibodies were collected and fixed by adding a cross-linking agent, formaldehyde, to stabilize the interactions between chromatin proteins and DNA. ..

    Double Immunofluorescence Staining:

    Article Title: Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.
    Article Snippet: Although immune mechanisms can suppress tumour growth, tumours establish potent, overlapping mechanisms that mediate immune evasion.. Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms.. Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system.



    Similar Products

    stimulation  (MedChemExpress)
    92
    MedChemExpress stimulation
    Stimulation, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccl28/MEC%2FCCL28%2C+Human/pm39075504-81-18-21
    Average 92 stars, based on 1 article reviews
    stimulation - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    ccl28  (R&D Systems)
    93
    R&D Systems ccl28
    (A) Representative histograms showing surface CCR10 expression on IgE + (red) and IgG1 + (blue) gated cells; the filled grey histogram shows the isotype control staining. The accompanying graph shows CCR10 MFI on the gated IgE + and IgG1 + cells. (B) Representative plots of CCR10 expression on IgE + and IgG1 + GC-like B cells, PBs, and PCs. CCR10 MFI across the different IgE + and IgG1 + cell populations from several experiments. (C) The dot plots show the frequency of IgE + and IgG1 + cells after 3h of migration in response to RPMI only or two different concentrations of <t>CCL28,</t> 25nM (300 ng/mL) and 125nM (1.5 μg/mL). (D) CCL28 induced migration shown as a percentage of the IgE + and IgG1 + cells migrating in response to RPMI control. (E) The migration capacity of IgE + and IgG1 + GC-like B cells, plamablasts, and PC in response to CCL28. (F) CCL28 induced migration shown as a percentage of the cells migrating in response to RPMI control. Data are mean + s.d. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison test (B, D, F) or paired two-tailed t -test with Welch’s correction (A); *p< 0.05; **p< 0.01.
    Ccl28, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccl28/Recombinant+Human+CCL28+Protein%2C+CF/bio_rxiv__64898__2025__12__18__695109-133-29-30
    Average 93 stars, based on 1 article reviews
    ccl28 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    human ccl28  (R&D Systems)
    93
    R&D Systems human ccl28
    Fig. 2 Tumor-derived <t>CCL28</t> recruits pericytes to promote vascular normalization in the tumor microenvironment
    Human Ccl28, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccl28/Human+CCL28+Antibody/pm39075504-90-10-14
    Average 93 stars, based on 1 article reviews
    human ccl28 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    ccl28  (MedChemExpress)
    92
    MedChemExpress ccl28
    Fig. 2 Tumor-derived <t>CCL28</t> recruits pericytes to promote vascular normalization in the tumor microenvironment
    Ccl28, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccl28/MEC%2FCCL28%2C+Human/pm39075504-81-20-21
    Average 92 stars, based on 1 article reviews
    ccl28 - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    human ccl2 elisa kit  (R&D Systems)
    94
    R&D Systems human ccl2 elisa kit
    Figure 1. Plasma and urine <t>CCL2</t> levels between AKI and non-AKI patients at hospital and ICU admission. **p < 0.01; ***p < 0.001; ****p < 0.0001.
    Human Ccl2 Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccl28/Human+CCL28+ELISA+Kit+(Colorimetric)/10__1080_slash_0886022x__2024__2313171-59-12-16
    Average 94 stars, based on 1 article reviews
    human ccl2 elisa kit - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    pcmv ccl28 vector  (OriGene)
    92
    OriGene pcmv ccl28 vector
    Figure 1. Plasma and urine <t>CCL2</t> levels between AKI and non-AKI patients at hospital and ICU admission. **p < 0.01; ***p < 0.001; ****p < 0.0001.
    Pcmv Ccl28 Vector, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccl28/CCL28+(NM_148672)+Human+Tagged+ORF+Clone/pm38307549-81-7-9
    Average 92 stars, based on 1 article reviews
    pcmv ccl28 vector - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    human ccl28 protein  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc human ccl28 protein
    Figure 1. Plasma and urine <t>CCL2</t> levels between AKI and non-AKI patients at hospital and ICU admission. **p < 0.01; ***p < 0.001; ****p < 0.0001.
    Human Ccl28 Protein, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccl28/Human+IL-5+Recombinant+Protein/pm38307549-104-16-43
    Average 93 stars, based on 1 article reviews
    human ccl28 protein - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Representative histograms showing surface CCR10 expression on IgE + (red) and IgG1 + (blue) gated cells; the filled grey histogram shows the isotype control staining. The accompanying graph shows CCR10 MFI on the gated IgE + and IgG1 + cells. (B) Representative plots of CCR10 expression on IgE + and IgG1 + GC-like B cells, PBs, and PCs. CCR10 MFI across the different IgE + and IgG1 + cell populations from several experiments. (C) The dot plots show the frequency of IgE + and IgG1 + cells after 3h of migration in response to RPMI only or two different concentrations of CCL28, 25nM (300 ng/mL) and 125nM (1.5 μg/mL). (D) CCL28 induced migration shown as a percentage of the IgE + and IgG1 + cells migrating in response to RPMI control. (E) The migration capacity of IgE + and IgG1 + GC-like B cells, plamablasts, and PC in response to CCL28. (F) CCL28 induced migration shown as a percentage of the cells migrating in response to RPMI control. Data are mean + s.d. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison test (B, D, F) or paired two-tailed t -test with Welch’s correction (A); *p< 0.05; **p< 0.01.

    Journal: bioRxiv

    Article Title: IgE-producing cells on the move: CCR2 is a key regulator of IgE + plasma cell migration

    doi: 10.64898/2025.12.18.695109

    Figure Lengend Snippet: (A) Representative histograms showing surface CCR10 expression on IgE + (red) and IgG1 + (blue) gated cells; the filled grey histogram shows the isotype control staining. The accompanying graph shows CCR10 MFI on the gated IgE + and IgG1 + cells. (B) Representative plots of CCR10 expression on IgE + and IgG1 + GC-like B cells, PBs, and PCs. CCR10 MFI across the different IgE + and IgG1 + cell populations from several experiments. (C) The dot plots show the frequency of IgE + and IgG1 + cells after 3h of migration in response to RPMI only or two different concentrations of CCL28, 25nM (300 ng/mL) and 125nM (1.5 μg/mL). (D) CCL28 induced migration shown as a percentage of the IgE + and IgG1 + cells migrating in response to RPMI control. (E) The migration capacity of IgE + and IgG1 + GC-like B cells, plamablasts, and PC in response to CCL28. (F) CCL28 induced migration shown as a percentage of the cells migrating in response to RPMI control. Data are mean + s.d. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison test (B, D, F) or paired two-tailed t -test with Welch’s correction (A); *p< 0.05; **p< 0.01.

    Article Snippet: More specifically, we tested the migration of IgE + and IgG1 + cells in response to recombinant human CXCL12 (R&D systems; 300ng/mL), CCL2 (Biolegend; 10ng/mL, 100ng/mL and 300ng/mL) and CCL28 (R&D systems; 300ng/mL and 1.5ug/mL).

    Techniques: Expressing, Control, Staining, Migration, Comparison, Two Tailed Test

    Fig. 2 Tumor-derived CCL28 recruits pericytes to promote vascular normalization in the tumor microenvironment

    Journal: Journal of experimental & clinical cancer research : CR

    Article Title: Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma.

    doi: 10.1186/s13046-024-03135-3

    Figure Lengend Snippet: Fig. 2 Tumor-derived CCL28 recruits pericytes to promote vascular normalization in the tumor microenvironment

    Article Snippet: Chromatin Immunoprecipitation (ChIP) Briefly, pericytes treated with or without recombinant human CCL28 or CCR3 (R&D Systems, MAB155-100) neutralizing antibodies were collected and fixed by adding a cross-linking agent, formaldehyde, to stabilize the interactions between chromatin proteins and DNA.

    Techniques: Derivative Assay

    Fig. 3 Tumor-derived CCL28 promotes the expression of angiopoietin-1 via CCR3 in pericytes

    Journal: Journal of experimental & clinical cancer research : CR

    Article Title: Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma.

    doi: 10.1186/s13046-024-03135-3

    Figure Lengend Snippet: Fig. 3 Tumor-derived CCL28 promotes the expression of angiopoietin-1 via CCR3 in pericytes

    Article Snippet: Chromatin Immunoprecipitation (ChIP) Briefly, pericytes treated with or without recombinant human CCL28 or CCR3 (R&D Systems, MAB155-100) neutralizing antibodies were collected and fixed by adding a cross-linking agent, formaldehyde, to stabilize the interactions between chromatin proteins and DNA.

    Techniques: Derivative Assay, Expressing

    Fig. 6 CCL28 is involved in bevacizumab-mediated vascular normalization

    Journal: Journal of experimental & clinical cancer research : CR

    Article Title: Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma.

    doi: 10.1186/s13046-024-03135-3

    Figure Lengend Snippet: Fig. 6 CCL28 is involved in bevacizumab-mediated vascular normalization

    Article Snippet: Chromatin Immunoprecipitation (ChIP) Briefly, pericytes treated with or without recombinant human CCL28 or CCR3 (R&D Systems, MAB155-100) neutralizing antibodies were collected and fixed by adding a cross-linking agent, formaldehyde, to stabilize the interactions between chromatin proteins and DNA.

    Techniques:

    Fig. 7 A schematic diagram of tumor microenvironment modulation effects of CCL28

    Journal: Journal of experimental & clinical cancer research : CR

    Article Title: Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma.

    doi: 10.1186/s13046-024-03135-3

    Figure Lengend Snippet: Fig. 7 A schematic diagram of tumor microenvironment modulation effects of CCL28

    Article Snippet: Chromatin Immunoprecipitation (ChIP) Briefly, pericytes treated with or without recombinant human CCL28 or CCR3 (R&D Systems, MAB155-100) neutralizing antibodies were collected and fixed by adding a cross-linking agent, formaldehyde, to stabilize the interactions between chromatin proteins and DNA.

    Techniques:

    Figure 1. Plasma and urine CCL2 levels between AKI and non-AKI patients at hospital and ICU admission. **p < 0.01; ***p < 0.001; ****p < 0.0001.

    Journal: Renal Failure

    Article Title: Assessment of urine CCL2 as a potential diagnostic biomarker for acute kidney injury and septic acute kidney injury in intensive care unit patients

    doi: 10.1080/0886022x.2024.2313171

    Figure Lengend Snippet: Figure 1. Plasma and urine CCL2 levels between AKI and non-AKI patients at hospital and ICU admission. **p < 0.01; ***p < 0.001; ****p < 0.0001.

    Article Snippet: The CCL2 levels in plasma and urine were measured using a commercial human CCL2 ELISA kit (R&D Systems, Bio-Techne, Minneapolis, USA) following the manufacturer’s instructions.

    Techniques: Clinical Proteomics

    Figure 2. The predictive performance of urine CCL2 for AKI by ROC analysis. (A) ROC curve. (B) AUC and prediction sensitivity and specificity.

    Journal: Renal Failure

    Article Title: Assessment of urine CCL2 as a potential diagnostic biomarker for acute kidney injury and septic acute kidney injury in intensive care unit patients

    doi: 10.1080/0886022x.2024.2313171

    Figure Lengend Snippet: Figure 2. The predictive performance of urine CCL2 for AKI by ROC analysis. (A) ROC curve. (B) AUC and prediction sensitivity and specificity.

    Article Snippet: The CCL2 levels in plasma and urine were measured using a commercial human CCL2 ELISA kit (R&D Systems, Bio-Techne, Minneapolis, USA) following the manufacturer’s instructions.

    Techniques:

    Figure 3. Plasma and urine CCL2 levels between SAKI and non-septic AKI patients at hospital and ICU admission. ***p < 0.001.

    Journal: Renal Failure

    Article Title: Assessment of urine CCL2 as a potential diagnostic biomarker for acute kidney injury and septic acute kidney injury in intensive care unit patients

    doi: 10.1080/0886022x.2024.2313171

    Figure Lengend Snippet: Figure 3. Plasma and urine CCL2 levels between SAKI and non-septic AKI patients at hospital and ICU admission. ***p < 0.001.

    Article Snippet: The CCL2 levels in plasma and urine were measured using a commercial human CCL2 ELISA kit (R&D Systems, Bio-Techne, Minneapolis, USA) following the manufacturer’s instructions.

    Techniques: Clinical Proteomics

    Figure 4. The predictive performance of urine CCL2 for SAKI by ROC analysis. (A) ROC curve. (B) AUC and prediction sensitivity and specificity.

    Journal: Renal Failure

    Article Title: Assessment of urine CCL2 as a potential diagnostic biomarker for acute kidney injury and septic acute kidney injury in intensive care unit patients

    doi: 10.1080/0886022x.2024.2313171

    Figure Lengend Snippet: Figure 4. The predictive performance of urine CCL2 for SAKI by ROC analysis. (A) ROC curve. (B) AUC and prediction sensitivity and specificity.

    Article Snippet: The CCL2 levels in plasma and urine were measured using a commercial human CCL2 ELISA kit (R&D Systems, Bio-Techne, Minneapolis, USA) following the manufacturer’s instructions.

    Techniques: